Information only — no products are sold on this website.
RT10 · Pen · Metabolic research — investigational
An investigational triple receptor agonist under clinical development. It is NOT approved for public use anywhere and should be regarded strictly as a research and clinical-trial compound.
Retatrutide is an investigational multi-receptor agonist being evaluated in sponsor-run clinical trials. It is not an approved medicine in South Africa or elsewhere, and it is not authorised for public use or supply outside of an approved clinical trial.
Development programmes describe combined agonism at GIP, GLP-1 and glucagon receptors, pathways involved in appetite regulation and energy metabolism. Mechanistic descriptions here are informational only.
Phase 2 trial results have been published in peer-reviewed journals. Late-stage trials are ongoing. Investigational results do not constitute approval, and long-term safety data are not complete.
Information only — availability subject to applicable law, prescription/authorisation, and licensed healthcare/pharmacy channels. Nothing on this page is an offer to sell, and no dosing or self-administration guidance is provided.
South Africa — compliance notice
SAHPRA has publicly warned about unregistered peptide products being marketed to the South African public. In general, products intended to diagnose, treat, or otherwise alter bodily functions require registration or authorisation before they may lawfully be sold. ELLIVON BIOSCIENCES publishes reference information only and directs all clinical questions to registered healthcare professionals and licensed pharmacy channels.